IPP Bureau
Lupin signs distribution agreement with Medis for Orphan Drug NaMuscla@
By IPP Bureau - February 09, 2022
NDM disorders are a group of rare, inherited neuromuscular disorders which is characterized by the inability to relax muscles following voluntary contraction
Dr Reddy’s launch generic version of Vasostrict in the US
By IPP Bureau - February 09, 2022
The Vasostrict brand market had U.S. sales of approximately US $ 878.5 million MAT for the most recent twelve months ending in December 2021 according to IQVIA Health
Abbott announces world's first implant of dual-chamber leadless pacemaker in pivotal trial
By IPP Bureau - February 08, 2022
Proprietary implant-to-implant (i2i) device technology is used for communication between two implanted leadless pacemakers to regulate the heart rate
Azurity Pharma gets USFDA approval for Fleqsuvy
By IPP Bureau - February 08, 2022
Nearly 1 million people are living with multiple sclerosis in the United States. Spasticity is a commonly reported symptom for MS, with an estimated prevalence of spasticity of 67%
Thermo Fisher Scientific launches rapid environmental PCR testing solution
By IPP Bureau - February 08, 2022
Rapid testing produces air sample results in 30 minutes
Everest Medicines' trodelvy approved in Singapore for second-line metastatic triple-negative breast cancer
By IPP Bureau - February 08, 2022
Singapore Health Sciences Authority (HSA) approval marks the first in a series of expected approvals of trodelvy in Asia
Biogen and Xbrane announce commercialization and license agreement for biosimilar to treat rheumatoid arthritis
By IPP Bureau - February 08, 2022
Under the terms of the agreement, Biogen will make an upfront payment of US $ 8 million to Xbrane
Wockhardt gets CDSCO nod to export 100 million doses of Sputnik vaccines
By IPP Bureau - February 08, 2022
Wockhardt has entered into an agreement with Russian Direct Investment Fund and Enso Healthcare to manufacture and supply Sputnik V and Sputnik Light vaccines against Covid-19
GlaxoSmithKline Pharmaceuticals delivers strong financials in Q3FY22
By IPP Bureau - February 08, 2022
EBITDA from Continuing Operations at Rs. 582 crore recorded a growth of 31 %.
Merck KGaA restructures life science business to support long-term growth
By IPP Bureau - February 08, 2022
Newly formed Life Science Services business unit to offer fully integrated CDMO and Contract Testing Services
Granules India Q3FY22 PAT at Rs 100.88 cr.
By IPP Bureau - February 08, 2022
Granules India has reported consolidated financial results for the period ended December 31, 2021
AsterDM Healthcare Q3FY22 PAT at Rs 148.34 cr.
By IPP Bureau - February 08, 2022
Aster DM Healthcare has reported consolidated financial results for the period ended December 31, 2021
Suven Pharma Q3FY22 PAT at Rs. 160.06 crore
By IPP Bureau - February 08, 2022
Suven Pharmaceuticals has reported consolidated financial results for the period ended December 31, 2021.
Lupin receives approval from USFDA for Arformoterol Tartrate inhalation
By IPP Bureau - February 08, 2022
Arformoterol Tartrate had estimated annual sales of US $ 251 million in the U.S. (IQVIA MAT December 2021)
Origin Materials and Minafin form strategic partnership for biobased chemicals
By IPP Bureau - February 08, 2022
The partnership includes multiple collaboration areas and is an important milestone for bringing cost-competitive biobased products to the market, with applications in the pharmaceutical, agricultural, cosmetics and personal care, and automotive industries
